Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab consolidation in high-risk LBCL
NCT06956092Phase 4Not yet recruiting
- Sponsor
- Zhengzhou University
- Start
- May 2025
- Primary completion
- Jun 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhengzhou University. Planned start May 2025; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06956092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06956092.